pharma · Cancer on the prostatic bed · Prostate cancer at risk of developing metastatic lesions
A.C.O.M. - Advanced
A.C.O.M. - Advanced Center Oncology
A.C.O.M. - Advanced is a pharma organization headquartered in EU. Primary therapeutic focus areas include Cancer on the prostatic bed, Prostate cancer at risk of developing metastatic lesions. NovaPharmaNews links 2 clin
EU HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Programs
- 2
- Drugs
- 4
- Patents
- 1
P.64Cu.003.01
Phase 3 · small molecule · Prostate cancer at risk of developing metastatic lesions
P.64Cu.003.01 for Prostate cancer at risk of developing metastatic lesions is a Phase 3 program (small_molecule) at A.C.O.M. - Advanced Center Oncology with 1 ClinicalTrials.gov record(s).
Internal code P.64Cu.003.01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- A.C.O.M. - Advanced Center Oncology
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Prostate cancer at risk of developing metastatic lesions
- Status
- active
- Trials
- 1